Pfizer and Biogen have come up with a match made in heaven, with one company seeking to dump neuroscience assets while the other needs to build them up. But while Pfizer may have done well to off-load the candidate, current evidence suggests that Biogen will need to keep shopping around if it …


Link to Full Article: Read Here

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!